Block randomization at the kit preparation stage.

Enrollment (n = 48)

Inclusion and exclusion criteria verification; baseline symptoms assessment; completion of the SF-36 Health Survey.

Kit number assignment according to the sequence of study participation.

Omeprazole (n = 23)
20 mg am + 20 mg pm for 2 weeks

Placebo (n = 25)
1 caps. am + 1 caps. pm for 2 weeks

Symptom assessment; completion of the SF-36 Health Survey

Placebo (n = 23)
1 caps. am + 1 caps. pm for 2 weeks

Omeprazole (n = 25)
20 mg am + 20 mg pm for 2 weeks

Symptom assessment; completion of the SF-36 Health Survey